Latest TAT Stories
RICHMOND, Calif., Feb. 28, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of positive preliminary clinical data from its Phase 1 trial (SB-728-902).
GEDERA, Israel, February 3, 2011 /PRNewswire-FirstCall/ -- TAT Technologies Ltd.
Tiny variants in a protein that alerts the immune system to the presence of infection may underlie the rare ability of some individuals to control HIV infection without the need for medications.
GEDERA, Israel, July 20, 2010 /PRNewswire-FirstCall/ -- TAT Technologies Ltd.
RICHMOND, Calif., July 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
PLEASANTON, Calif., June 4 /PRNewswire-FirstCall/ -- Roche Molecular Diagnostics (SIX: RO, ROG: OTCQX: RHHBY) announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood.
Two new studies showing that protein bits produced by unusual "reading" of the HIV genome can induce immune responses will appear online in the Journal of Experimental Medicine on Jan. 11 (www.jem.org).
While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
We are advised by TAT Technologies Ltd that journalists and other readers should disregard the news release "TAT Technologies Announcing the Entry Into a New Manufacturing Contract With Embraer, Empresa Brasileira de Aeronautica S.A." nasdaq:TATTF, issued earlier today over PR Newswire, as it will
- A transitional zone between two communities containing the characteristic species of each.